John J Mariani

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. pmc Psychostimulant treatment of cocaine dependence
    John J Mariani
    Division of Substance Abuse, New York State Psychiatric Institute, New York, NY 10032, USA
    Psychiatr Clin North Am 35:425-39. 2012
  2. pmc Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes
    John J Mariani
    New York State Psychiatric Institute, Division on Substance Abuse, 1051 Riverside Drive, Unit 66, New York, NY 10032, USA
    Drug Alcohol Depend 113:249-51. 2011
  3. pmc Effects of research setting on observed depressive symptoms in marijuana users
    John J Mariani
    Division on Substance Abuse, New York State Psychiatric Institute, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    J Subst Abuse Treat 37:431-4. 2009
  4. pmc Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review
    John J Mariani
    Division on Substance Abuse, New York State Psychiatric Institute, New York, New York 10032, USA
    Am J Drug Alcohol Abuse 34:683-91. 2008
  5. pmc Antisocial behavioral syndromes in cocaine and cannabis dependence
    John J Mariani
    New York State Psychiatric Institute, Division on Substance Abuse, New York, NY 10032, USA
    Am J Drug Alcohol Abuse 34:405-14. 2008
  6. pmc Quetiapine treatment of zolpidem dependence
    John J Mariani
    New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    Am J Addict 16:426. 2007
  7. pmc Treatment strategies for co-occurring ADHD and substance use disorders
    John J Mariani
    New York State Psychiatric Institute, New York, New York, USA
    Am J Addict 16:45-54; quiz 55-6. 2007
  8. ncbi request reprint A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal
    John J Mariani
    Department of Psychiatry, Division on Substance Abuse, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Am J Addict 15:76-84. 2006
  9. pmc Comparison of clinical trial recruitment populations: treatment-seeking characteristics of opioid-, cocaine-, and cannabis-using participants
    John J Mariani
    Division on Substance Abuse, New York State Psychiatric Institute, New York, NY 10032, USA
    J Subst Abuse Treat 40:426-30. 2011
  10. pmc Comparison of substance use milestones in cannabis- and cocaine-dependent patients
    Jonathan T Horey
    Division on Substance Abuse, New York Psychiatric Institute, New York, New York 10022, USA
    J Addict Dis 31:60-6. 2012

Research Grants

Collaborators

Detail Information

Publications23

  1. pmc Psychostimulant treatment of cocaine dependence
    John J Mariani
    Division of Substance Abuse, New York State Psychiatric Institute, New York, NY 10032, USA
    Psychiatr Clin North Am 35:425-39. 2012
    ..Biases against using controlled substances as a treatment for cocaine dependence should be challenged, much in the way the use of agonist treatment transformed the treatment of opioid dependence despite initial resistance from the field...
  2. pmc Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes
    John J Mariani
    New York State Psychiatric Institute, Division on Substance Abuse, 1051 Riverside Drive, Unit 66, New York, NY 10032, USA
    Drug Alcohol Depend 113:249-51. 2011
    ..Individual variability in use practices limits the utility of this method to estimating within-subject comparisons, rather than between subject comparisons...
  3. pmc Effects of research setting on observed depressive symptoms in marijuana users
    John J Mariani
    Division on Substance Abuse, New York State Psychiatric Institute, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    J Subst Abuse Treat 37:431-4. 2009
    ..e., treatment-seekers are more likely to be experiencing some degree of clinical distress), it is notable that treatment-seeking, and not marijuana use per se, is associated with significantly higher rates of depression...
  4. pmc Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review
    John J Mariani
    Division on Substance Abuse, New York State Psychiatric Institute, New York, New York 10032, USA
    Am J Drug Alcohol Abuse 34:683-91. 2008
    ..There is pre-clinical and clinical evidence that levetiracetam, a newer generation anticonvulsant medication, may be efficacious in the treatment of co-occurring alcohol use and anxiety disorders...
  5. pmc Antisocial behavioral syndromes in cocaine and cannabis dependence
    John J Mariani
    New York State Psychiatric Institute, Division on Substance Abuse, New York, NY 10032, USA
    Am J Drug Alcohol Abuse 34:405-14. 2008
    ..Antisocial behavioral syndromes are commonly diagnosed in patients with SUD and future research should evaluate prognostic implications of AABS compared to ASPD in a variety of clinical treatment settings...
  6. pmc Quetiapine treatment of zolpidem dependence
    John J Mariani
    New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    Am J Addict 16:426. 2007
  7. pmc Treatment strategies for co-occurring ADHD and substance use disorders
    John J Mariani
    New York State Psychiatric Institute, New York, New York, USA
    Am J Addict 16:45-54; quiz 55-6. 2007
    ..Recommendations for treatment planning and clinical management for patients with co-occurring ADHD and SUD are discussed...
  8. ncbi request reprint A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal
    John J Mariani
    Department of Psychiatry, Division on Substance Abuse, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Am J Addict 15:76-84. 2006
    ..Given gabapentin's favorable pharmacokinetic profile, further study of its effectiveness in treating alcohol withdrawal is warranted...
  9. pmc Comparison of clinical trial recruitment populations: treatment-seeking characteristics of opioid-, cocaine-, and cannabis-using participants
    John J Mariani
    Division on Substance Abuse, New York State Psychiatric Institute, New York, NY 10032, USA
    J Subst Abuse Treat 40:426-30. 2011
    ..These results have implications for clinical trial recruitment and public health efforts directed at encouraging cannabis-dependent individuals to seek treatment...
  10. pmc Comparison of substance use milestones in cannabis- and cocaine-dependent patients
    Jonathan T Horey
    Division on Substance Abuse, New York Psychiatric Institute, New York, New York 10022, USA
    J Addict Dis 31:60-6. 2012
    ..To compare the progression of substance use milestones between cocaine- and cannabis-dependent patients...
  11. pmc A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence
    Adam Bisaga
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Drug Alcohol Depend 119:e23-9. 2011
    ..Preclinical findings suggest that the inhibition of NMDA glutamatergic neurotransmission may have beneficial effects in the treatment of opioid dependence...
  12. pmc Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial
    Frances R Levin
    New York State Psychiatric Institute, Division of Substance Abuse, New York, NY 10032, USA
    Drug Alcohol Depend 116:142-50. 2011
    ..Future trials might test higher doses, combinations of dronabinol with other medications with complementary mechanisms, or with more potent behavioral interventions...
  13. pmc Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
    Maria A Sullivan
    Columbia University and the New York State Psychiatric Institute, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA Electronic address
    Drug Alcohol Depend 133:80-5. 2013
    ..We hypothesized that opiate use would moderate the effect of naltrexone, specifically, that opiate-positive urines precede dropout in the placebo group, but not in the active-medication groups...
  14. pmc The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders
    Elias Dakwar
    New York State Psychiatric Institute, Columbia University, College of Physicians and Surgeons, 1051 Riverside Dr, Unit 66, New York, NY 10032, USA
    J Clin Psychiatry 73:e1372-8. 2012
    ..The aim of this study was to determine the sensitivity, specificity, and positive and negative predictive values of 3 commonly used ADHD screening instruments in cocaine-dependent individuals...
  15. pmc A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period
    Adam Bisaga
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Drug Alcohol Depend 111:97-104. 2010
    ..Targeting the latter subgroup may advance medication development efforts...
  16. pmc A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence
    Adam Bisaga
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York NY Electronic address
    J Subst Abuse Treat 46:546-52. 2014
    ..07). Adding memantine does not appear to increase the effectiveness of injectable XR naltrexone as a relapse prevention strategy in opioid dependence and may lead to an increase in treatment drop-out. ..
  17. pmc Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial
    John J Mariani
    Division of Substance Abuse, New York State Psychiatric Institute, New York 10032, USA
    Biol Psychiatry 72:950-6. 2012
    ..Amphetamine and topiramate have both shown promise for the treatment of cocaine dependence in preclinical and early-stage clinical studies...
  18. pmc Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement
    Abigail J Herron
    St Luke s Roosevelt Hospital Center, 324 W 108th Street, 505, New York, NY 10025, USA
    Drug Alcohol Depend 128:77-82. 2013
    ..This study compares qualitative visual inspection of fluorescence to quantitative fluorometric analysis of riboflavin concentration in its ability to detect the presence of riboflavin in urine...
  19. ncbi request reprint Open-label pilot study of quetiapine treatment for cannabis dependence
    John J Mariani
    New York State Psychiatric Institute, Division of Substance Abuse, New York
    Am J Drug Alcohol Abuse 40:280-4. 2014
    ..The recommended maximum target dose for cannabis-dependent patients is 300 mg daily. These preliminary data support further evaluation of quetiapine as a treatment for cannabis dependence. ..
  20. pmc A comparison of psychosocial and cognitive functioning between depressed and non-depressed patients with cannabis dependence
    Alex M Secora
    Division of Substance Abuse, New York State Psychiatric Institute, New York, NY 10032, USA
    J Addict Dis 29:325-37. 2010
    ..Based on the authors' results, they concluded that the additive effects of cannabis dependency and depression may only be limited to psychosocial domains and may not extend to cognitive functioning...
  21. ncbi request reprint Pharmacotherapy for alcohol-related disorders: what clinicians should know
    John J Mariani
    Department of Psychiatry, Division on Substance Abuse, Columbia University, College of Physicians and Surgeons, USA
    Harv Rev Psychiatry 12:351-66. 2004
    ..The routine exclusion of alcohol-dependent patients from pharmacotherapy trials of psychiatric disorders presents a barrier to gathering more data. Recommendations for future research are discussed...
  22. pmc Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol
    Frances R Levin
    New York State Psychiatric Institute, Division on Substance Abuse, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA
    Drug Alcohol Depend 106:65-8. 2010
    ..We propose that the lack of THCV detection may be due to the variability of available cannabis strains smoked by marijuana users in community settings...
  23. ncbi request reprint A case report of maintenance valproic acid treatment failing to protect against alcohol withdrawal
    John J Mariani
    Am J Addict 14:397-8. 2005

Research Grants2

  1. Anticonvulsant Pharmacotherapy for Sedative-Hypnotic Use Disorders
    John Mariani; Fiscal Year: 2007
    ..Development of an effective treatment strategy would have a direct positive impact on public health. ..